Wells Fargo analyst Derek Archila downgraded Horizon Therapeutics to Equal Weight from Overweight with a price target of $116.50, down from $118, after the company reached deal to be acquired by Amgen (AMGN) for $116.50 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Horizon Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Horizon Therapeutics downgraded to Hold from Buy at Stifel
- Unusually active option classes on open December 12th
- Amgen (NASDAQ:AMGN) to Buy Horizon for $27.8B; HZNP Stock Rallies
- Amgen to acquire Horizon Therapeutics for $116.50 per share in cash